Studies genetic changes in high-risk endometrial cancer patients
Collects cancer genetic information from people with high-risk endometrial cancer.
Plain-language title generated from the registry record
Registry title: Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
Key facts
- Where
- Rochester, United StatesSee the site
Where in United States
- Mayo Clinic in RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT07062016
- Record updated
- 3 November 2026
- Original description
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.Read full original descriptionShow less
MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.
Inclusion: Age ≥ 18 years; Planned complete surgical staging at Mayo Clinic. Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon's discretion; At least one preoperative or postoperative feature of aggressive disease [International Federation of Gynecology and Obstetrics (FIGO) staging used throughout this protocol]; Preoperatively:; Biopsy with grade 3 endometrioid endometrial cancer (EC) or non-endometrioid EC; Patients with FIGO grade 1-2 EC with evidence of extrauterine disease on imaging (CT, MRI, or PET); Postoperatively:; Endometrial cancer (FIGO) with one or more established risk factors:; Non-endometrioid histology; Grade 3; Lymphovascular space invasion (LVSI), ≥ 50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node OR; Stage II to IV (FIGO) EC; Provide written informed consent; Willingness to provide mandatory blood specimens for correlative research; Willingness to provide mandatory tissue specimens for correlative research; Willingness to return to registering site for clinical follow-up.
Exclusion: Patient receiving or who has received neoadjuvant chemotherapy; Pre-operative pregnancy.